FDA GUIDANCE DOCUMENT: Sterile Drug Products Produced by Aseptic Processing —Current Good Manufacturing Practice

The FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice, is a foundational document that outlines the agency’s current thinking and cGMP expectations for manufacturing sterile drugs. Aseptic processing is a method in which the drug product, container, and closure are sterilized separately and then assembled in a highly controlled environment. The guidance details a comprehensive, risk-based approach to contamination control, emphasizing that every aspect of the process must be meticulously designed, validated, and executed to maintain sterility. Terminal sterilization is the preferred method when feasible; aseptic processing is reserved for cases where terminal sterilization is not possible.

The guidance provides a detailed framework for designing, validating, and controlling aseptic manufacturing processes in compliance with 21 CFR Parts 210 and 211. It addresses facility and equipment design, personnel qualification, environmental monitoring, aseptic process simulation (media fills), sterilization methods, and the use of barrier technologies.

Core principle—contamination control. Because aseptic processing cannot rely on a terminal sterilization step, sterility must be assured throughout processing. All potential sources of contamination—personnel, environment, equipment, and materials—must be identified and controlled. Critical areas where sterile product/components are exposed must be maintained under ISO 5 (Class 100) unidirectional airflow, with adjacent areas generally maintained at ISO 7.

Facility design & airflow. Cleanrooms must demonstrate proper classification and airflow by dynamic smoke studies. ISO 5 zones should achieve ≤3520 particles/m³ (≥0.5 µm) during operations. Unidirectional airflow must sweep particles away from exposed product, and velocity setpoints should be justified (commonly ~0.45 m/s ±20%).

Environmental monitoring (EM). A written EM program must define locations, frequency, alert/action levels, and trending procedures. Monitoring methods include active air sampling, passive settle plates, surface sampling, and personnel monitoring. ISO 5 samples should normally yield no microbial contaminants; adverse findings require prompt investigation and corrective action.

Personnel training, qualification, and monitoring. Personnel are the greatest contamination risk. Operators must be trained and periodically requalified in aseptic technique, cleanroom behavior, and gowning. Gowning qualification requires demonstration of proper donning and monitoring of gloves/gown surfaces during operations. Sanitizing gloves immediately before sampling is discouraged as it can mask contamination.

Aseptic process simulations (media fills). Media fills are the cornerstone of process validation. A microbiological growth medium (e.g., Tryptic Soy Broth) is substituted for product and run through the entire process, including routine and non-routine interventions. Incubate filled units for at least 14 days (or at two temperatures for ≥7 days each). Recommended acceptance criteria:
• <5,000 units: 0 contaminated (1 = investigation + repeat; 2 = revalidation)
• 5,000–10,000 units: 0 contaminated preferred (1 = investigation; 2 = revalidation)
• >10,000 units: 0 contaminated preferred (1 = investigation; 2 = revalidation)
Any contaminated unit must be investigated; repeated positives indicate loss of control.

Barrier and isolator technologies. FDA strongly encourages technologies that minimize human intervention in the critical zone. Restricted Access Barrier Systems (RABS) and isolators provide physical separation of operators from the sterile environment, significantly reducing contamination risk.